| Description |
1 online resource |
| Series |
Respiratory medicine |
|
Respiratory medicine (New York, N.Y.)
|
| Contents |
Intro -- Preface -- Contents -- Contributors -- Part I: Overview -- Chapter 1: The Lung-Blood Interface -- Introduction -- Airway Structure -- Features of the Blood Vessel Tree -- Bronchial Artery System -- Convection-Diffusion in Airway Conductance -- Interdependence of Alveolar pO2, and Independence of Arterial pO2 -- Oxygen Diffusion Capacity -- Red Blood Cell as Vehicles of Gas Exchange -- Ultrastructure of the Alveolus -- Type I Alveolar Epithelial Cells -- Type II Alveolar Epithelial Cells -- Maintaining the Alveolar Lining -- Capillary Endothelium -- Alveolar Fluid Balance -- Hose Defense Mechanisms of the Lung -- Conclusion -- References -- Chapter 2: Leukocyte Kinetics and Migration in the Lungs -- Introduction -- Intravital Microscopy of the Lung Microcirculation in Mice -- The Blood-Air Barrier in the Lung -- Leukocyte Kinetics in the Noninflamed Lung -- Leukocyte Kinetics in the Inflamed Lung -- Neutrophil Sequestration and Retention in the Pulmonary Capillaries -- Neutrophil Emigration into the Alveolar Air Space -- Conclusion -- References -- Part II: Acute Pulmonary Manifestations Arising From Primary Hematologic Disorders -- Chapter 3: Sickle Cell Disease and Acute Chest Syndrome: Mechanisms and Pathogenenesis -- Introduction -- Clinical Laboratory Predictors of ACS -- Postmortem Findings -- Genetic Modifiers -- Pathogenesis of ACS -- Hypoxia and Ischemia Reperfusion Injury -- iNKT Cell Activation -- Fat Emboli -- Hemolysis -- Extracellular Heme -- Extracellular Heme Crisis -- Neutrophil Extracellular Traps (NETs) -- Preclinical Murine ACS Model -- Conclusion: A Mechanistic Model of ACS Pathogenesis -- References -- Chapter 4: Sickle Cell Disease and Acute Chest Syndrome: Epidemiology, Diagnosis, Management, Outcomes -- Introduction -- Acute Chest Syndrome -- Epidemiology and Clinical Presentation -- Diagnosis -- Management |
|
Outcomes -- Conclusion -- References -- Chapter 5: Thrombophilias and Acute Pulmonary Thromboembolic Disease -- Inherited Thrombophilias -- Acquired Thrombophilic States and Thromboembolism -- Paroxysmal Nocturnal Hemoglobinuria -- Heparin-Induced Thrombocytopenia -- Antiphospholipid Syndrome -- Myeloproliferative Neoplasms -- Acute Pulmonary Thromboembolic Disease -- Introduction -- Pathogenesis -- Risk Factors and Stratification -- Diagnosis -- Management -- Prognosis -- References -- Chapter 6: Bleeding Disorders: Diagnosis and Treatment of Hemorrhagic Complications in the Intensive Care Unit -- Inherited Bleeding Disorders -- von Willebrand Disease -- Background -- Classification -- Genetics -- Clinical Manifestations -- Diagnostic Studies -- Treatment -- Hemophilia -- Background -- Genetics -- Clinical Manifestations -- Hemarthroses -- Soft-Tissue Hematomas -- Other Bleeding Manifestations -- Diagnosis -- Treatment -- Complications -- Chronic Hemophilic Arthropathy -- Viral Infections -- Inhibitors -- Acquired Bleeding Disorders -- Coagulopathy -- Anticoagulants -- Parental Anticoagulants -- Oral Anticoagulants -- Disseminated Intravascular Coagulation -- Liver Disease -- Trauma -- Platelet disorders -- Thrombocytopenia -- Medications -- Infections -- Disseminated Intravascular Coagulation -- Liver Disease -- Platelet Dysfunction -- Medications -- Hematologic Disorders -- Uremia -- Iatrogenic Bleeding -- References -- Chapter 7: Acute Pulmonary Manifestations of Hematologic Malignancies -- Pulmonary Infection -- Bacterial Infections -- Fungal Infections -- Viral Infections -- Noninfectious Acute Pulmonary Manifestations -- Pulmonary Hemorrhage -- Pulmonary Edema -- Pulmonary Leukostasis -- Therapeutic Complications -- Retinoic Acid Syndrome -- Effects of Tyrosine Kinase Inhibitors |
|
Tyrosine Kinase Inhibitors of BCR-ABL: Imatinib, Dasatinib, and Nilotinib -- Anti-lymphocyte Monoclonal Antibodies -- Rituximab -- Engraftment Syndrome -- Acute Graft Versus Host Disease (GVHD) -- Conclusion -- References -- Chapter 8: Acute Pulmonary Complications of Bone Marrow and Stem Cell Transplantation -- Introduction -- Acute Respiratory Failure After HCT -- Epidemiology of Acute Respiratory Failure -- Diagnostic Considerations -- Noninfectious Etiologies -- Lung Injury Syndromes, Early Onset -- Idiopathic Pneumonia Syndrome -- Lung Injury Syndromes, Late Onset -- Cryptogenic Organizing Pneumonia -- Bronchiolitis Obliterans Syndrome -- Drug-Induced Pneumonitis -- Pulmonary Alveolar Proteinosis -- Pulmonary Vascular Disease -- Infectious Etiologies -- Cytomegalovirus -- Community Respiratory Viruses -- Invasive Fungal Disease -- Key Points -- References -- Part III: Transfusion-Related Complications -- Chapter 9: Storage Lesion: Evolving Concepts and Controversies -- Storage of Red Blood Cell Components -- Potential Contributors to the RBC Storage Lesion -- RBC Morphology and Deformability -- 2,3-Diphosphoglycerate (DPG) -- Adenosine Triphosphate (ATP), pH, Lactate -- Glutathione and NADPH -- Oxidation of Cellular Lipids and Proteins -- Membrane Loss and Microvesicles -- Supernatant Lipid Accumulation -- Phosphatidylserine -- Desialylation of RBCs -- Decreased Membrane Expression of CD47 -- Clinical Consequences of Transfusion of Stored RBCs -- RBC Hemolysis -- Intravascular Hemolysis -- Effects of Free Hemoglobin/Heme in the Circulation -- Imbalance Between Nitric Oxide and Reactive Oxygen Species -- Platelet and Hemostatic Activation -- Heme and ATP-Mediated Activation of the Innate Immune System -- Extravascular Hemolysis -- Clinical Studies of Fresh Versus Old RBC Transfusions -- Summary -- References |
|
Chapter 10: Transfusion and Acute Respiratory Distress Syndrome: Pathogenesis and Potential Mechanisms -- Introduction -- Transfusion and ARDS in Clear Temporal Relationship: TRALI -- Pathogenesis of TRALI: Two-Hit Mechanism -- Pathogenesis of TRALI: Importance of Host Factors in the First Hit -- The First Hit -- Specific Patient Risk Factors -- Pathogenesis of TRALI: Antibody Mediated TRALI -- HLA and HNA Antibodies -- Downstream Host Response in Antibody Mediated TRALI -- Pathogenesis of TRALI: Non-antibody-mediated TRALI -- Soluble Mediators -- Cellular Changes -- Downstream Host Response in Non-antibody-mediated TRALI -- Pathogenesis of TRALI: Threshold Model -- Transfusion and ARDS: The Association -- Transfusion and ARDS: Is There a Two-Hit Mechanism? -- Transfusion and ARDS: Risk Factors -- Patient Risk Factors -- Transfusion Risk Factors -- Transfusion and ARDS: Different Pathogenesis from TRALI? -- Causative Factors in ARDS Following Transfusion -- Downstream Events in ARDS Following Transfusion -- Explanatory Model for the Occurrence of ARDS Following Transfusion -- Model for the Association Between Transfusion and ARDS -- References -- Chapter 11: Transfusion and Acute Respiratory Distress Syndrome: Clinical Epidemiology, Diagnosis, Management, and Outcomes -- Overview -- Epidemiology -- Definition -- Mechanisms of TRALI -- Risk Factors -- Recipient Risk Factors -- Donor and Blood Component Risk Factors -- Incidence -- Blood Product Variation -- Diagnosis -- Clinical Presentation -- Diagnostic Workup -- Blood Bank Reporting -- Differential Diagnosis -- Possible TRALI -- Other Transfusion Reactions -- Management -- Supportive Therapy -- Oxygen -- Hemodynamic Support -- Medications -- Steroids -- Diuretics -- Prevention -- Restrictive Transfusion Strategy -- Implicated Donor Deferral -- Multiparous Female Donor Deferral |
|
Leukocyte Reduced Blood -- Solvent Detergent Plasma -- Outcomes -- Mortality Rates -- Sequelae of TRALI -- References -- Chapter 12: Transfusion Associated Circulatory Overload -- Introduction -- Definition -- Epidemiology -- Risk Factors -- Clinical Presentation -- Pathophysiology -- Diagnostic Evaluation -- Prevention -- Treatment -- Acute Support -- Volume Removal -- Reporting -- Outcomes -- Conclusion -- References -- Chapter 13: Transfusion-Related Immunomodulation (TRIM): From Renal Allograft Survival to Postoperative Mortality in Cardiac Surgery -- Enhanced Survival of Renal Allografts -- Clinical Studies of Adverse TRIM Effects -- TRIM Effects Mediated by Allogeneic Mononuclear Cells -- TRIM Effects Mediated by White-Cell-Derived Soluble Mediators -- TRIM Effects Mediated by Soluble Molecules Circulating in Allogeneic Plasma -- Association of Non-white-cell-reduced Allogeneic Blood Transfusion with Postoperative Mortality -- Observational Studies "Before-and-After" White-Cell Reduction -- Conclusions -- References -- Index |
| Notes |
Includes index |
|
Print version record |
| Subject |
Lungs -- Blood-vessels -- Diseases.
|
|
Lungs -- Diseases.
|
|
Acute Chest Syndrome
|
|
Hematologic Diseases -- complications
|
|
Transfusion Reaction
|
|
Lung Diseases
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Lungs -- Blood-vessels -- Diseases
|
|
Lungs -- Diseases
|
| Form |
Electronic book
|
| Author |
Lee, Janet S., editor
|
|
Donahoe, Michael P., editor
|
| ISBN |
9783319419121 |
|
3319419129 |
|
